{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Cohort+B%29",
    "query": {
      "intervention": "Placebo (Cohort B)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 421,
    "total_pages": 43,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Cohort+B%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T14:39:35.973Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07399678",
      "title": "Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Overweight or Obese Adults",
        "Overweight or Obese, Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "ALV-100",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alveus Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 180,
      "start_date": "2025-12-29",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-09-28T14:39:35.973Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Columbus, Ohio",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07399678"
    },
    {
      "nct_id": "NCT04478708",
      "title": "Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "maridebart cafraglutide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 110,
      "start_date": "2020-08-07",
      "completion_date": "2022-11-18",
      "has_results": true,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-09-28T14:39:35.973Z",
      "location_count": 3,
      "location_summary": "Anaheim, California • Tustin, California • Miami, Florida",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04478708"
    },
    {
      "nct_id": "NCT04208178",
      "title": "Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced HER2+Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Alpelisib",
          "type": "DRUG"
        },
        {
          "name": "Alpelisib matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 19,
      "start_date": "2020-07-16",
      "completion_date": "2027-02-26",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-09-28T14:39:35.973Z",
      "location_count": 2,
      "location_summary": "Fayetteville, Arkansas • Los Angeles, California",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04208178"
    },
    {
      "nct_id": "NCT00820950",
      "title": "A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib phosphate cream",
          "type": "DRUG"
        },
        {
          "name": "Dovonex® calcipotriene 0.005%",
          "type": "DRUG"
        },
        {
          "name": "Diprolene® AF betamethasone dipropionate 0.05% cream.",
          "type": "DRUG"
        },
        {
          "name": "Placebo cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 29,
      "start_date": "2007-05-31",
      "completion_date": "2009-04-30",
      "has_results": true,
      "last_update_posted_date": "2022-02-08",
      "last_synced_at": "2026-09-28T14:39:35.973Z",
      "location_count": 6,
      "location_summary": "Vallejo, California • Boston, Massachusetts • Rochester, New York + 3 more",
      "locations": [
        {
          "city": "Vallejo",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00820950"
    },
    {
      "nct_id": "NCT00821652",
      "title": "Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumors"
      ],
      "interventions": [
        {
          "name": "NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod",
          "type": "DRUG"
        },
        {
          "name": "NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nina Bhardwaj",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2009-02",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-01-08",
      "last_synced_at": "2026-09-28T14:39:35.973Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00821652"
    },
    {
      "nct_id": "NCT06491550",
      "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "AZD4144- Part A",
          "type": "DRUG"
        },
        {
          "name": "Placebo- Part A",
          "type": "DRUG"
        },
        {
          "name": "AZD4144- Part B",
          "type": "DRUG"
        },
        {
          "name": "Placebo- Part B",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin and Furosemide- Part C",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin, Furosemide, and AZD4144 Part C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 91,
      "start_date": "2024-07-15",
      "completion_date": "2025-06-11",
      "has_results": false,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-09-28T14:39:35.973Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Brooklyn, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06491550"
    },
    {
      "nct_id": "NCT06086613",
      "title": "A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Osteogenesis Imperfecta"
      ],
      "interventions": [
        {
          "name": "AGA2115",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Angitia Incorporated Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 72,
      "start_date": "2023-10-03",
      "completion_date": "2024-10-17",
      "has_results": false,
      "last_update_posted_date": "2025-01-10",
      "last_synced_at": "2026-09-28T14:39:35.973Z",
      "location_count": 1,
      "location_summary": "Lake Forest, California",
      "locations": [
        {
          "city": "Lake Forest",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06086613"
    },
    {
      "nct_id": "NCT05099510",
      "title": "Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Natrunix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "XBiotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2022-01-19",
      "completion_date": "2022-08-08",
      "has_results": true,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-09-28T14:39:35.973Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05099510"
    },
    {
      "nct_id": "NCT02982915",
      "title": "Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Aging Frailty"
      ],
      "interventions": [
        {
          "name": "Longeveron Mesenchymal Stem Cells (LMSCs)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone High Dose Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Longeveron Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "65 Years to 90 Years"
      },
      "enrollment_count": 62,
      "start_date": "2016-11",
      "completion_date": "2022-09",
      "has_results": false,
      "last_update_posted_date": "2022-11-04",
      "last_synced_at": "2026-09-28T14:39:35.973Z",
      "location_count": 6,
      "location_summary": "Coral Gables, Florida • Fort Myers, Florida • Miami, Florida + 2 more",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02982915"
    },
    {
      "nct_id": "NCT06528457",
      "title": "Study to Examine the Effects of Oral Fenretinide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "ISLA101",
          "type": "DRUG"
        },
        {
          "name": "Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Island Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 15,
      "start_date": "2024-09-05",
      "completion_date": "2025-07-21",
      "has_results": false,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-09-28T14:39:35.973Z",
      "location_count": 1,
      "location_summary": "East Syracuse, New York",
      "locations": [
        {
          "city": "East Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06528457"
    }
  ]
}